Program
danuglipron
Also written as “PF-06882961”, “Danuglipron” and “PF-06882961 (Cohorts 1 and 2)”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Pfizer.
Furthest: phase 2, since Jun 11, 201918 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 180 open or running | phase 2since Jun 11, 2019 | Oct 10, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Oct 10, 2017.
- May 7, 2018Phase 1 study in Diabetes Mellitus, Type 2NCT03538743 · 98 enrolled · United States
- Jun 11, 2019Phase 2 study in Diabetes Mellitus, Type 2NCT03985293 · 412 enrolled · United States, Bulgaria, Canada and more
- Jul 16, 2020Phase 1 study in Healthy VolunteerNCT04495140 · 6 enrolled · Netherlands
- Sep 11, 2020Phase 1 study in Diabetes Mellitus, Type 2NCT04552470 · 37 enrolled · Japan
- Oct 21, 20203 phase 1 studiesNCT04604496, NCT04616027, NCT04616339
- Oct 30, 2020Phase 2 study in Diabetes MellitusNCT04617275 · 151 enrolled · United States
- Nov 3, 2020Phase 1 study in ObesityNCT04621227 · 16 enrolled · United States
- Jan 11, 2021Phase 2 study in ObesityNCT04707313 · 628 enrolled · United States, Canada, Japan and more
- Mar 29, 2021Phase 1 study in Healthy VolunteerNCT04839393 · 27 enrolled · United States
- May 12, 2021Phase 1 study in Diabetes Mellitus, Type 2NCT04889157 · 20 enrolled · China
- Oct 13, 2021Phase 1 study in Healthy AdultsNCT05093205 · 35 enrolled · United States
- Nov 22, 2023Phase 1 study in Healthy ParticipantsNCT06153758 · 33 enrolled · United States
- Aug 21, 2024Phase 1 study in ObesityNCT06568731 · 23 enrolled · United States
- Mar 12, 2025Phase 1 study in OverweightNCT06910839 · 21 enrolled · United States
TargetBeta
GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06910839Overweight · United States | 1 | Terminated | May 1, 2025 | 21 |
| NCT06568731Obesity · United States | 1 | Completed | Dec 18, 2024 | 23 |
| NCT06153758Healthy Participants · United States | 1 | Completed | Sep 30, 2024 | 33 |
| NCT05093205Healthy Adults · United States | 1 | Completed | Jul 6, 2022 | 35 |
| NCT04889157Diabetes Mellitus, Type 2 · China | 1 | Completed | Feb 17, 2022 | 20 |
| NCT04839393Healthy Volunteer · United States | 1 | Completed | Oct 10, 2021 | 27 |
| NCT04707313Obesity · United States, Canada, Japan and more | 2 | Completed | Sep 13, 2023 | 628 |
| NCT04621227Obesity · United States | 1 | Completed | May 13, 2021 | 16 |
| NCT04617275Diabetes Mellitus · United States | 2 | Completed | Nov 17, 2021 | 151 |
| NCT04616339Overweight and/or Obesity · Belgium | 1 | Completed | Jul 19, 2021 | 31 |
| NCT04616027Diabetes Mellitus, Type 2 · United States | 1 | Completed | Feb 18, 2022 | 42 |
| NCT04604496Hepatic Impairment · United States | 1 | Completed | Jan 10, 2022 | 24 |
| NCT04552470Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Mar 25, 2021 | 37 |
| NCT04495140Healthy Volunteer · Netherlands | 1 | Completed | Oct 15, 2020 | 6 |
| NCT03985293Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more | 2 | Completed | Jun 8, 2021 | 412 |
| NCT03538743Diabetes Mellitus, Type 2 · United States | 1 | Completed | May 23, 2019 | 98 |
| NCT03492697Healthy Subjects · United States | 1 | Completed | Jul 18, 2018 | 12 |
| NCT03309241Healthy Subjects · United States | 1 | Completed | Feb 21, 2018 | 25 |
How it is read
Names in the registry
- “PF-06882961”, 16 entries
- “Danuglipron”, 2 entries
- “PF-06882961 (Cohorts 1 and 2)”, 1 entry
- “PF-06882961 (Cohort 3)”, 1 entry
- “PF-06882961 20 mg”, 1 entry
Codes read as this program: PF06882961.
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Diabetes Mellitus, Type 2, 5 studies
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.